Trials / Withdrawn
WithdrawnNCT00625079
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of California, Los Angeles · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that sildenafil may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.
Detailed description
The purpose of this study is to evaluate the use of sildenafil in patients with pulmonary fibrosis and PH being considered for lung transplantation. We hypothesize that not only will sildenafil improve functionality and QOL in the pre-transplant setting but it may also improve primary graft dysfunction after lung transplantation.
Conditions
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Pulmonary Hypertension
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sildenafil | the dose of sildenafil will be 20mg three times per day (orally) |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-06-01
- Completion
- 2009-12-01
- First posted
- 2008-02-28
- Last updated
- 2018-05-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00625079. Inclusion in this directory is not an endorsement.